Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
For much of the world, the full promise of liquid biopsy exceeds purchasing power.
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
You may also be interested in...
Illumina sued Guardant last year, claiming Guardant’s founders stole trade secrets related to blood biopsy diagnostics. The companies have agreed to drop that dispute and share specimen samples for cancer research.
Illumina faces a difficult decision now that the US FTC has formally rejected its attempt to re-acquire Grail, the sequencing company it originally sold in 2016. The FTC and European regulators say the merger would stifle competition but the company plans to appeal the ruling.
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.